Showing results (71-80 of 81) with videos related to
Sort By:
Pageof 9
BMJ Open|May 4, 2023
Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDAStephany Hiayev, Einat Shacham-Shmueli, Matitiahu Berkovitch, et al.Ejhaem|July 18, 2022
Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomibPaul G Richardson, Arnon Nagler, Dina Ben-Yehuda, et al.Nature Medicine|February 23, 2021
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencingYael C Cohen, Mor Zada, Shuang-Yin Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyRakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.Haematologica|March 5, 2026
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trialsKatarina Uttervall, Martin K Kortum, Aurore Perrot, et al.Nature Medicine|December 8, 2018
Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myelomaGuy Ledergor, Assaf Weiner, Mor Zada, et al.The Lancet. Oncology|July 18, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trialVania Hungria, Paweł Robak, Marek Hus, et al.The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaVania Hungria, Pawel Robak, Marek Hus, et al.Blood|May 12, 2026
Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival AnalysisEfstathios Kastritis, Giovanni Palladini, Monique C Minnema, et al.The New England Journal of Medicine|June 30, 2021
Daratumumab-Based Treatment for Immunoglobulin Light-Chain AmyloidosisEfstathios Kastritis, Giovanni Palladini, Monique C Minnema, et al.Pageof 9